![]() A review on stem cell therapy for multiple sclerosis: special focus on human embryonic stem cells. The Tisch Center team has launched a phase II trial of this therapy. Stem cells taken from the patients blood and bone marrow are then re-infused. Effect of nonmyeloablative hematopoietic stem cell transplantation vs continued disease-modifying therapy on disease progression in patients with relapsing-remitting multiple sclerosis. The treatment uses chemotherapy to destroy the faulty immune system. doi:10.21037/sci.2019.10.06īurt RK, Balabanov R, Burman J, et al. After approximately three years, about 6 of the stem cell group experienced relapses, while 60 of the people in the control group receiving standard treatment relapsed. Safety and efficacy of stem cell therapy for treatment of neural damage in patients with multiple sclerosis. Long-term clinical outcome of hematopoietic stem cell transplantation in multiple sclerosis. Mesenchymal stem cells and iPSCs.īoffa G, Massacesi L, Inglese M, et al. aHSCT in MS (autologous hematopoietic stem cell transplantation). Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis. Sormani MP, Muraro PA, Schiavetti I, et al. The discovered potential of mesenchymal stem cells (MSC) in treating Multiple Sclerosis (MS) has culminated in the launch of MESCAMS (MEsenchymal Stem cell therapy for CAnadian MS patients), a phase II clinical trial that is funded in part by the MS Scientific Research Foundation, Research Manitoba and A&W Food Services of Canada Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |